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Abstract
Modern genetics has shown the power of modifying microbes, from viruses to 
bacteria to algae, to produce desirable agricultural products. Nevertheless, gene 
additions or modification have led to relatively few products in the marketplace 
due partly to costs of regulation, but also to the challenges of production, deliv-
ery and application. Some products with gene loss have been marketed, notably 
Agrobacterium radiobacter with a deletion for plasmid transfer, some veterinary 
vaccines and plants with one or a few genes from microbes for plant protec-
tion. Concerns over using live microbes are centered on recombination with wild 
type strains, potential for environmental risks, market acceptance, market scope, 
monitoring costs, and costs of production. The challenges in microbial agricul-
tural plant biotechnology far outweigh those in medical and veterinary biotech-
nology because of pricing potential, larger markets and controlled environments 
in which modified microbes can function. Nevertheless, the promise and need 
for control of plant pathogens for which little or no plant resistance is available 
warrant continued efforts in this area. Veterinary uses of modified microbes will 
continue and be more widely accepted. Plants “vaccinated” with genes for plant 
protection are increasingly used but their safety is still questioned and debated. 
Products such as enzymes from GMOs will continue to enter the marketplace and 
be accepted with few questions.
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1 Introduction
Genetically modified microorganisms (GMOs) based on recombinant DNA 
techniques have been constructed since the 1970s. The potential for beneficial 
use was recognized very early, as was their potential risk through misuse, in-
tentional or accidental. This dilemma remains with us in the twenty-first cen-
tury. GMOs have also been known as genetically engineered microorganisms 
(GEOs) or genetically modified microbes (GMMs). Many of the issues related 
to the use of engineered microbes in agriculture have been presented earlier 
(Ryder 1994; Wilson and Lindow 1993; Wrubel et al. 1997), in a symposium 
on “The Scientist’s Role in the Controversy Over Genetic Engineering, Regu-
lation and Utilization of Microorganisms” (Vidaver 1989), and more recently 
in a study by the National Academy of Sciences (NRC 2004). However, the 
bulk of these presentations and discussions appeared two decades or more 
ago in the early days of modern genetics and genetic engineering. Today, 
the ease and lower cost of nucleic acid sequencing for genome analysis, im-
proved methods of detection of microorganisms and specific sequences, new 
discoveries in genetic manipulation, and synthetic biology raise new issues 
to ponder and new approaches to assessing microbial ecology and the risks 
and benefits of GMOs in agriculture. In this chapter, we deal principally with 
commercialization of products used for plant and animal production and 
protection in agriculture.
2 Current Status of GMOs
2.1 Regulation
GMOs are regulated in the U.S. based on the intended use, whereas in Can-
ada regulation is a part of novel product oversight. Microbial GMOs in plant 
agriculture agents, ranging from viroids to nematodes (Table 1), are under 
the jurisdiction of the Environmental Protection Agency (EPA) (see else-
where in this book) if the objective of their use is for pest control. In Canada 
jurisdiction is by Health Canada. Protective veterinary products for animals 
Table 1. Relative potential of microorganisms as GMOs for use in agriculture
Agent Ease of genetic Ease of Ease of 
 manipulation production application
Viroids  Variable Challenging Difficult
Viruses  Variable Challenging Challenging
Bacteria  Variable Easy Easy
Fungi  Challenging Challenging Challenging
Oomycetes  Difficult Difficult Difficult
Protozoa  Difficult Difficult Difficult
Algae  Difficult Challenging Difficult
Nematodes  Difficult Difficult Variable
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and fish are regulated and licensed by the Center for Veterinary Biologics 
of the United States Department of Agriculture’s (USDA) Animal and Plant 
Health Inspection Service (APHIS) in the U.S. and by the Canadian Food In-
spection Agency (CFIA) in Canada. APHIS also has authority under the Plant 
Protection and Quarantine program over introduction and release into the 
environment of organisms that are or may be plant pests.
2.2 Commercial Product Overview
GMOs have a minor use in agriculture. Products are limited because of costs 
of regulation and marketplace determination of availability and applications. 
Since 1976, the U. S. EPA has compiled an inventory of about 82,000 chem-
icals produced in or imported into the U.S., many of which are used in ag-
riculture (Schierow 2009). That period of over-three decades coincides with 
the rise of modern genetics and tools for modification of microorganisms. 
To date, there are 63 commercial products that we have identified, compris-
ing living microbes, plants modified with microbial genes for pest protec-
tion, and veterinary vaccines. There are also a couple dozen enzymes derived 
from GMOs used in the food industry. This is hardly a robust number and 
cause for concern or alarm.
Bacteria, fungi and viruses are the major candidates of choice for genetic 
manipulation. Commercial products for protection could be in any form, 
but the most common is with the use of live or non-viable agents applied for 
competitive exclusion or direct competition for receptor sites on plant parts 
(Wilson and Lindow 1994), or as vaccines in animals (Jackwood et al. 2008; 
Meeusen et al. 2007). All of the agents approved thus far are primarily effec-
tive when used prior to exposure of the infectious agent. About 22 enzymes 
derived from GMOs are used in the food industry worldwide (Olempska-
Beer et al. 2006).
2.3 Vaccines in Animal Agriculture
There are a number of genetically engineered veterinary viral and bacte-
rial vaccines, including gene-deleted vaccines and live recombinant chimera 
viruses that combine parts of two infective viral genomes (Jackwood et al. 
2008; Meeusen et al. 2007). These vaccines are in three categories: live genet-
ically modified microbes (viruses or bacteria with one or more genes deleted 
or inactivated or carrying a foreign gene), recombinant inactivated vaccines 
(subunit vaccines containing only part of the whole organism) and genetic 
vaccines (nucleic acids or DNA with foreign genes). There are 21 of these 
commercially available for treatment of a wide variety of animals: ruminants, 
swine, poultry and companion animals. However, these are still a minor part 
of the commercial vaccine market. As of 2010, the USDA Center for Veteri-
nary Biologics has listed 28 vaccines categorized as seven non-replicating re-
combinant antigen vaccines, two nucleic acid-mediated vaccines, four live 
gene-deleted vaccines and 15 live vectored vaccines.
V i d a V e r  e t  a l .  i n  R e g u l a t i o n  o f  a g R i c u l t u R a l  B i o t e c h n o l o g y  ( 2012 )98
2.4 Microorganisms Associated with Plants and Plant Pests
A small number of free-living GMOs have been approved for use since the 
last century (Amarger 2002); only those in current use are listed in Table 2. 
These have a Biopesticide Regulatory Action Document (BRAD) that indi-
cates current status in the U.S. Note that strains are specifically mentioned. 
For example Agrobacterium radiobacter K1026 (Jones and Kerr 1989) is a Tra– 
(transfer negative) derivative of A. radiobacter K84, a naturally occurring bac-
terium effective against crown gall, caused by a tumorigenic relative, A. tu-
mefaciens. A transferable plasmid in K84 also carries a gene for a specialized 
antibiotic or bacteriocin effective against A. tumefaciens. Deletion of the Tra+ 
gene prevents the rare transfer to A. tumefaciens, which could make it resis-
tant to biocontrol. We were unable to find records of GMOs used outside the 
U.S., except for Australia where A. radiobacter K1026 originated; it has been 
used commercially since 1988 for reducing crown gall infection of stone 
fruits, such as peach and cherry and ornamentals, notably roses (Ryder 1994).
In the case of the Bacillus thuringiensis (Bt) derivatives, each has differing 
insecticidal properties. The corresponding wild-type (natural) strains have 
been used for about 70 years, including in organic farming. The modified 
strains or host bacteria attach to plant receptors more easily and are more re-
sistant to UV light degradation than the parent strains. The host bacterium, 
dead or alive, has no known deleterious effects on animals, plants or hu-
mans. Extensive information on the analysis conducted by EPA of Bt in sev-
eral formulations has been summarized by Mendelsohn et al. (2003).
There are a miniscule number of potential products that could provide 
protection for plants from infectious agents. The historic experiments with a 
Pseudomonas syringae ice-minus deletion summarized by Lindow (1989) and 
Wilson and Lindow (1993) did not lead to a viable product, although an un-
modified strain is used now to protect plants from frost under a narrow tem-
perature range. There was a transient commercialization of Sinorhizobium 
(Rhizobium) meliloti RMSPC-2 (EPA 1997, 1998) as seed inoculants for alfalfa. 
The strain had genes to enhance nitrogen fixation and nutrient utilization, 
as well as an antibiotic resistant marker gene (http://epa.gov/biotech_rule/
pubs/factdft6.htm ). The commercial transfer of the Bt delta endotoxin gene 
to the endophyte Clavibacter xyli for control of the corn ear worm (Tomasino 
et al. 1995) lost to competition with the development of Bt genes transformed 
as integral parts of the plant cell.
Table 2. Registered genetically modified microbes and primary use in plant agriculture
Microorganism Use
Agrobacterium radiobacter K1026 Protection of roots from crown gall
Pseudomonas fluorescens (killed) with Bacillus  Insecticidal spray (no reproduction 
   thuringiensis delta endotoxins (endotoxins      of host bacterium) 
   from B.t. strains aizawai, Kurstaki, or San Diego)  
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2.5 Microbial Genes as Plant Protectants
Microbial genes inserted into plants have been widely adopted since the mid-
1990s. In the U.S., these genes for plant protection are classified as “PIPs” 
or plant-incorporated protectants, of which there are now about 40 regis-
tered with the EPA ( http://www.epa.gov/oppbppd1/biopesticides/index.
htm#pips ). The majority use genes from Bt strains for insect control (Men-
delsohn et al. 2003). Virus-protected papaya and cucurbit plants have been 
commercialized for several years but are not listed on the PIP website. The 
latest candidate is the coat protein gene of Plum pox virus used to protect 
stone fruit trees which has recently been approved for commercialization 
(http://www.epa.gov/oppbppd1/biopesticides/ingredients/tech_docs/
brad_006354.pdf ).
3 Constraints
Not surprisingly, the use of dead or inactivated microbes (e.g. vaccines for 
animals) has been more widely accepted and commercialized than the use 
of live microbes or chemicals for plant protection (Table 3). Microbes are 
likely to be viewed more negatively in agriculture if they are able to repli-
cate. Questions continue to be raised about their survival, persistence, con-
tamination, spread, efficacy of expression of the beneficial trait(s), and gene 
transfer. This is the case even though no substantive differences have been 
found between GMOs and the corresponding parent strains (Amarger 2002; 
Wilson and Lindow 1994). Although substantial equivalence is becoming ac-
cepted for food safety/risk assessments (LeBlanc et al. 2010), we believe it is 
less likely to be used for agricultural and environmental applications.
4 Promises and Perils
Many opportunities and challenges remain. Containment remains an issue, 
but bioconfinement of microorganisms is possible genetically and physically 
(NRC 2004). Microbiologists and ecologists with little experience with plant 
Table 3. Strategies and attributes of introduced microorganisms and chemicals 
used in plant health and protection
Strategy/attribute Microorganisms Chemicals
Replication Yes (limited) No
Shelf-life Variable Long
Ecological contamination Rare Variable
Cost (research, production, regulatory) Variable High
Persistence Rare Variable
Specificity Common Rare
Safety Absolute (?); no reported adverse effects Variable
Market prospects Relatively limited Wide
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associated microbes remain concerned about reproduction, survival, and 
gene transfer to and from other microbes. When these questions have been 
dealt with experimentally and data provided for risk assessment, many can-
didate microbes may or may not be considered suitable for use. It is seldom 
recognized that thousands to millions of microbes colonize plants, includ-
ing imported inspected plants and bulbs, and most do so in a beneficial or 
neutral manner. Even so, the public is reluctant to use microorganisms, com-
pared with chemicals, because of the greater familiarity with germ and hu-
man disease causality rather than with the beneficial role of microbes in the 
environment (Table 3).
For animals, bio-engineered vaccines show great promise through using 
reverse genetics, non-replicating viral vectors, cytoplasmic replicating vi-
ruses (alpha viruses; positive stranded RNA viruses) and genetic vaccines, as 
well as benefiting from improved adjuvants and delivery systems (Patel and 
Heldens 2009).
New challenges and opportunities also lie with synthetic biology. For ex-
ample, viruses can be readily constructed de novo from commercially avail-
able nucleotides, and a partially synthetic bacterium has been constructed. 
Due to the high monetary costs of research and regulation, such constructs 
are not likely to be available in the agricultural sector in the near future. 
However, there is promise through plant genomics and limiting pathogen in-
vasion through novel resistance genes and RNAi approaches.
4.1 Challenges
Taxonomy is also a challenge to microbial production and use, and in risk as-
sessment. The scope of GMO regulation targets “intergenerics,” even though 
not all members of the same genus have similar habitats and traits. The use 
of taxa that include human and/or animal pathogens (e.g. Burkholderia cepa-
cia) has met with opposition by several groups, even when there is no evi-
dence of the strain’s ability to cause harm. And, whether Rhizobium (Bradyrhi-
zobium) inoculants that receive transgenes from other members of the species 
should be regulated under the Toxic Substances Control Act remains an open 
question, as it defines GMOs as intergeneric. This example is particularly 
pertinent because of its close taxonomic relationship to Agrobacterium, a ge-
nus composed largely of plant pathogens.
A number of critical needs must be met before more products are avail-
able and used in agriculture, including potential production of biofuels us-
ing GMOs (Glass 2008). It would be helpful to categorize microbes accord-
ing to risk groups and show that there are many that are generally regarded 
as compatible with the environment. A GRACE classification (Generally Re-
garded as Compatible with the Environment) would demonstrate to the pub-
lic that the commercial strains are in such a group, such as Rhizobium and 
Bradyrhizobium, among others. There should be clear differentiation between 
fears and risks. Risk assessments should be based on available science and, 
naturally, regulations and guidelines should be commensurate with the risk. 
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For small markets or specialty products, the equivalent of ORPHAN status 
might be considered. Delivery methodology needs to be improved in the 
plant sector, as is being done with human and animal medical vaccines. New 
technologies such as synthetic biology and nanotechnology need to be evalu-
ated for safe introduction into the environment. And public and media edu-
cation is essential.
Clearly, the marketplace for the private sector has been uneven. Few pros-
per with live GMOs. This appears to be largely due to insufficient sales com-
mensurate with perceived usefulness by the applicator and regulatory costs 
and constraints. The likelihood of increased numbers of free-living products 
in plant agriculture, based on 35 years of product analysis, is not promising. 
Public acceptance of transgenes in the products themselves has been wide-
spread, but continues to be challenged by certain sectors including organic 
foods. More research and education in multiple forums may alleviate such 
fears and enable more product development.
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